• Cellvizio®
    • Overview
    • Education
    • Economics
    • Indications
      • Gastroenterology
        • Barrett’s Esophagus
        • Pancreatic Cysts
        • Gastric Disease
        • Inflammatory Bowel Diseases
        • Irritable Bowel Syndrome – Food Intolerance
        • Bilio-Pancreatic Strictures
        • Colorectal Lesions
      • Pulmonology
        • Lung Nodules
        • Lung Transplant
      • Urology
  • Investors
    • Overview
    • Events and Presentations
    • Financials
    • Governance
  • About Us
    • Our Story
    • Team
      • Board of Directors
      • Leadership Team
    • Join Us
    • Commercial Network
  • Newsroom
    • News
    • Events
    • Press Coverage
  • US
    • INT
    • FR
Mauna Kea Technologies Announces the Successful Completion of Its Financial Restructuring and €6M Capital Raise 

Mauna Kea Technologies Announces the Successful Completion of Its Financial Restructuring and €6M Capital Raise 

by Elizabeth | Nov 14, 2025 | News

70% debt write-off, from €40M to €12M  Remaining debt to be repaid over 10 years, with 90% between the end of 2029 and the end of 2035  Capital raise of €6.1M extending cash runway to the second half of 2027  Paris and Boston, November 14, 2025 – 7:45 a.m....
Mauna Kea Technologies Announces the Successful Completion of Its Financial Restructuring and €6M Capital Raise 

Mauna Kea Technologies Exits Safeguard Proceedings Following Court Approval of its Plan and Initiates Minimum €5M Capital Raise 

by Elizabeth | Nov 13, 2025 | News, News

Safeguard plan approved by judgment of the Paris Commercial Court on November 12, 2025  Launch of a reserved capital increase in the form of shares with attached warrants (ABSA) at a price of €0.0973  Opening of an offer to retail investors via the...
Mauna Kea Technologies Announces the Successful Completion of Its Financial Restructuring and €6M Capital Raise 

Mauna Kea Technologies Announces It Has Secured Over €5M in Firm Subscription Commitments as Required for Its Capital Increase 

by Elizabeth | Oct 21, 2025 | News

New equity financing would provide the Company sufficient financial visibility to execute its strategic plan and achieve profitability  The future exercise of share subscription warrants (BSA) issued as part of the transaction could bring the total amount of the...
Mauna Kea Technologies Announces the Successful Completion of Its Financial Restructuring and €6M Capital Raise 

Mauna Kea Technologies Reports Third Quarter 2025 Revenue Up +16% at Constant Exchange Rates 

by Elizabeth | Oct 13, 2025 | News

U.S. sales surge +31% at constant exchange rates, with continued acceleration over the year  Commercial momentum highlighted by a doubling of U.S. system sales year-to-date  Adding to U.S. commercial team to support organic demand  Paris and Boston, Oct 13,...
Mauna Kea Technologies Announces the Successful Completion of Its Financial Restructuring and €6M Capital Raise 

Mauna Kea Technologies Announces the Terms of its Financing Under its Safeguard Plan 

by Elizabeth | Oct 8, 2025 | News, News

Capital increase of €5m to €8m through a private placement planned for the first half of November via the issuance of shares with attached warrants (ABSA)  Firm commitment from an investor for €2.7m, supplemented by indications of interest already exceeding the...
« Older Entries

Articles récents

  • Mauna Kea Technologies Announces the Successful Completion of Its Financial Restructuring and €6M Capital Raise 
  • Mauna Kea Technologies Exits Safeguard Proceedings Following Court Approval of its Plan and Initiates Minimum €5M Capital Raise 
  • Mauna Kea Technologies Announces It Has Secured Over €5M in Firm Subscription Commitments as Required for Its Capital Increase 
  • Mauna Kea Technologies Reports Third Quarter 2025 Revenue Up +16% at Constant Exchange Rates 
  • Mauna Kea Technologies Announces the Terms of its Financing Under its Safeguard Plan 

Commentaires récents

No comments to show.

Company Info

About Us

Join Us

Contact Us

Legal

Legal notice

Privacy policy

Cookie policy

Our websites

Cellvizio.net

cell-tolerance.com

Diagnosingbarretts.org

Diagnosingpancreaticcysts.org

Follow us

  • Follow
  • Follow
  • Follow
  • Follow
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}